Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Sinovac After 2009’s Flu Scare

publication date: Aug 16, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
In the second half of 2009, Sinovac Biotech was reporting blockbuster revenues because its flu vaccine sales went through the roof, as China faced the specter of a swine flu (H1N1) epidemic. This year, things are different. The public is not being inundated with daily news reports of flu deaths or increasing numbers of flu cases. And there isn’t any ensuing rush on the part of the general public to inoculate themselves from a potentially lethal dose of flu. It's not surprising that the company's stock has sold lower.  More details...

Stock Symbol: (NSDQ: SVA)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...